Ultragenyx Pharmaceutical (NASDAQ:RARE) Announces Quarterly Earnings Results, Beats Expectations By $0.32 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.32, Zacks reports. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The firm had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same quarter in the previous year, the firm earned ($1.17) EPS. The business’s quarterly revenue was up 28.5% on a year-over-year basis.

Here are the key takeaways from Ultragenyx Pharmaceutical’s conference call:

• Record quarterly revenue reached $214 million, up from contributions across Crysvita ($156 million), DOJOLVI ($27 million), Evkeeza ($21 million, up 50% year over year), and MEPSEVII ($10 million). Management reaffirmed full-year revenue and operating-expense guidance.
• Ultragenyx is preparing for potential FDA decisions on its first two gene therapies: DTX-401 for GSDIa on August 23 and UX-111 for Sanfilippo syndrome type A on September 19. The company said payer engagement, Qualified Treatment Center contracting, and launch preparations are progressing as planned.
• The Phase III ASPIRE trial of GTX-102 for Angelman syndrome remains on track for top-line results in September or October. Management said either the Bayley-4 cognition endpoint or the clinically meaningful Multi-Domain Responder Index could independently establish statistical success, although the results remain uncertain.
• Management reiterated a path to profitability in 2027, supported by double-digit growth from existing products, potential gene-therapy launches, expense discipline, and possible non-dilutive proceeds from monetizing priority review vouchers. The company ended the quarter with $436 million in cash and marketable securities.
• Setrusumab’s regulatory path remains uncertain after Phase III studies failed to meet their primary fracture-reduction endpoints. The FDA is considering alternative fracture analyses, but additional clinical data may be required, and the U.K. regulator indicated that a new randomized study could be necessary.

Ultragenyx Pharmaceutical Stock Down 2.5%

Shares of Ultragenyx Pharmaceutical stock traded down $0.64 on Wednesday, hitting $25.17. The stock had a trading volume of 1,287,457 shares, compared to its average volume of 2,221,582. Ultragenyx Pharmaceutical has a twelve month low of $18.29 and a twelve month high of $39.89. The business’s 50 day moving average is $27.77 and its two-hundred day moving average is $24.76. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -4.11 and a beta of 0.35.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, Director Shehnaaz Suliman sold 5,740 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the completion of the sale, the director directly owned 27,951 shares in the company, valued at $702,129.12. The trade was a 17.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Howard Horn sold 4,653 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $23.77, for a total value of $110,601.81. Following the completion of the transaction, the chief financial officer directly owned 105,689 shares in the company, valued at approximately $2,512,227.53. This represents a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 14,292 shares of company stock valued at $351,644. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently bought and sold shares of the business. State Street Corp grew its position in shares of Ultragenyx Pharmaceutical by 16.5% during the 4th quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company’s stock worth $98,970,000 after purchasing an additional 610,559 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Ultragenyx Pharmaceutical by 26.6% in the fourth quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company’s stock valued at $56,624,000 after buying an additional 516,781 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 614.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after buying an additional 1,864,164 shares during the period. Geode Capital Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 16.3% in the fourth quarter. Geode Capital Management LLC now owns 1,838,208 shares of the biopharmaceutical company’s stock valued at $42,287,000 after buying an additional 257,701 shares during the period. Finally, AQR Capital Management LLC grew its position in Ultragenyx Pharmaceutical by 82.3% during the fourth quarter. AQR Capital Management LLC now owns 1,360,497 shares of the biopharmaceutical company’s stock worth $31,291,000 after buying an additional 614,315 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reported second-quarter revenue of $214 million, up 28.5% year over year and well above the $183.08 million consensus estimate. The company’s adjusted loss of $0.90 per share also beat expectations for a $1.22 loss. Ultragenyx Q2 earnings report
• Positive Sentiment: Product performance remained solid, including $156 million in Crysvita revenue and $27 million from Dojolvi. Management reaffirmed 2026 revenue guidance of $730 million to $760 million, expects combined R&D and SG&A expenses to be flat to slightly lower, and remains on track to reach profitability in 2027. Ultragenyx second-quarter financial results
• Positive Sentiment: The company highlighted potential second-half catalysts, including two FDA PDUFA decisions and pivotal Phase 3 data for GTX-102 in Angelman syndrome.
• Neutral Sentiment: Wells Fargo lowered its price target from $47 to $45 but maintained an Overweight rating. The revised target still implies substantial upside from recent trading levels. Wells Fargo price-target update
• Negative Sentiment: Guggenheim also reduced its target, from $43 to $35, although it retained a Buy rating. Repeated target cuts can signal more cautious expectations and may be contributing to the stock’s weakness. Guggenheim price-target update
• Negative Sentiment: Ultragenyx remains unprofitable, reporting a negative net margin and a quarterly loss despite the earnings beat. Investors may also be focused on execution risk surrounding the company’s path to profitability and upcoming clinical and regulatory events.

Analysts Set New Price Targets

Several research firms have issued reports on RARE. Barclays dropped their price target on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Guggenheim lowered their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Wall Street Zen raised Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. Finally, Royal Bank Of Canada upped their price objective on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.82.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.